Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Gator who wrote (11036)	1/20/1999 10:47:00 AM
From: Joe Copia	Read Replies (4) \| Respond to of 25711

THREAD ALERT CYGS Read the following. CYGS seems to me to be a buy out target: Tuesday January 19, 3:04 pm Eastern Time Company Press Release Intracellular Synthesis of Telomeric Repeat Appears Lethal To Malignant Cells HOUSTON--(BUSINESS WIRE)--Jan. 19, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS) announced the positive results of its experimental expression of the (TTAGGG)n oligonucleotide sequence in HeLa cells. As expected, intracellular expression of the (TTAGGG)n oligo appeared to select against malignant cells which expressed the telomeric repeat whereas HeLa cultures transfected to express a control sequence of the same length continue to thrive. The company's ssDNA expression vector uses viral encoded genes to produce intracellular oligonucleotide sequences of any desired composition, which effectively avoids some of the major hurdles associated with antisense delivery. The vector can be described as a custom designed biological factory that synthesizes single-stranded DNA inside living cells. The researchers are able to program the sequences of ssDNA to be manufactured once the vector has entered a cell. It is anticipated that the ssDNA expression vector will soon allow biomedical research to graduate from cell cultures to live animal studies, especially those involving antisense technologies and therapies. The (TTAGGG)n sequence is one of many that have been shown in vitro to kill cancer cells. A series of subsequent in vivo studies are planned to demonstrate that the patented product performs as expected with a variety of catalogued sequences. ------------------------------------------------------------------------ Contact: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399